Founded in 1982, Baupost Group is one of the largest hedge funds in the world and has generated an average annual return of 19% since its inception.
Keep Reading →
August 22 - Hedge Funds, News - Comments
In its recent 13F filing with the U.S.
Keep Reading →
July 23 - Hedge Funds, News - Comments
Not bad for a single trade: Baupost Group appears to have made nearly $1 billion on just one of its stock picks.
Keep Reading →
June 9 - Hedge Funds - Comments
Alex Denner’s Sarissa Capital disclosed its holdings in its latest and first 13F filings.
Keep Reading →
February 14 - Hedge Funds, News - Comments
Baupost Group, managed by Seth Klarman, in a new 13F filing, reported the holdings from its equity portfolio for the fourth quarter.
Keep Reading →
February 14 - Hedge Funds, News - Comments
Baupost Group, a fund managed by Seth Klarman, is a large shareholder of Idenix Pharmaceuticals Inc (NASDAQ:IDIX).
Keep Reading →
February 5 - Hedge Funds, News - Comments
Hedgie Dan Loeb’s long winning streak continued in October — although a 20 percent drop in his high-profile activist target Sony Corporation (ADR) (NYSE:SNE) nearly wiped...
Keep Reading →
November 6 - Hedge Funds, News - Comments
Seth Klarman’s Baupost Group, one of the largest hedge funds in the world, reported in a new filing with the SEC increasing its exposure at Idenix Pharmaceuticals Inc (NASDAQ...
Keep Reading →
November 1 - Hedge Funds, News - Comments
According to a recent Bloomberg report, Gilead Sciences, Inc.
Keep Reading →
September 11 - News - Comments
Now, according to many of your fellow readers, hedge funds are viewed as delayed, old investment tools of a forgotten age.
Keep Reading →
September 6 - News - Comments
Now, according to many market players, hedge funds are viewed as bloated, outdated investment tools of a forgotten age.
Keep Reading →
September 3 - News - Comments
If you were to ask many traders, hedge funds are seen as useless, outdated investment vehicles of a period lost to current times.
Keep Reading →
August 30 - News - Comments
In the financial world, there are many indicators shareholders can use to analyze Mr. Market. A pair of the most innovative are hedge fund and insider trading activity.
Keep Reading →
August 30 - News - Comments
The biotech industry is a marvel among traders and investors because it can double your investment, or halve it, based on a single clinical study.
Keep Reading →
August 25 - News - Comments
Biotech's the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts...
Keep Reading →
July 22 - News - Comments
The biotech industry is a cutthroat one, with companies constantly racing to get new treatments approved by the FDA ahead of their rivals.
Keep Reading →
July 22 - News - Comments
Idenix Pharmaceuticals Inc (NASDAQ:IDIX) just can't catch a break.
Keep Reading →
June 28 - News - Comments
The easiest route would involve the companies with the biggest share price movements.
Keep Reading →
June 25 - News - Comments
Shares of small biotech Idenix Pharmaceuticals Inc (NASDAQ:IDIX) took a 32% nosedive this week, following unwelcome news from the U.S. Food and Drug Administration.
Keep Reading →
June 24 - News - Comments
Netflix, Inc. (NASDAQ:NFLX) had a good week.
Keep Reading →
June 24 - News - Comments
Are investors hitting the brakes on biotech? The biotech sector's one of the most boom-or-bust areas for investors, where fortunes can be won or lost.
Keep Reading →
June 24 - News - Comments
In the eyes of most traders, hedge funds are assumed to be worthless, old financial tools of yesteryear.
Keep Reading →
June 10 - News - Comments
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) was in 12 hedge funds' portfolio at the end of the first quarter of 2013.
Keep Reading →
June 6 - News - Comments
To most traders, hedge funds are seen as worthless, outdated investment tools of the past.
Keep Reading →
June 3 - News - Comments
Is Idenix Pharmaceuticals Inc (NASDAQ:IDIX) an excellent stock to buy now? Investors who are in the know are taking a bearish view.
Keep Reading →
June 3 - News - Comments
In today’s marketplace, there are tons of metrics shareholders can use to track stocks. A couple of the most innovative are hedge fund and insider trading sentiment.
Keep Reading →
June 3 - News - Comments
Small biotech companies have great investment potential if you can identify them properly.
Keep Reading →
April 24 - News - Comments
Is Dyax Corp. (NASDAQ:DYAX) the right investment to pursue these days? The best stock pickers are taking a bullish view.
Keep Reading →
April 1 - News - Comments
Have you checked your 401(k) or IRA balance lately? If you're like many people, the numbers brought forth a smile, with the major indexes hitting record highs.
Keep Reading →
March 30 - News - Comments
Is Idenix Pharmaceuticals Inc (NASDAQ:IDIX) the right investment to pursue these days? The smart money is in an optimistic mood.
Keep Reading →
March 27 - News - Comments
Gilead Sciences, Inc. (NASDAQ:GILD)' sofosbuvir with Johnson & Johnson (NYSE:JNJ) and Medivir's simeprevir are a match made in heaven.
Keep Reading →
March 5 - News - Comments
In the world of biotech stocks a lot of companies are starting to incorporate Hepatitis C treatments into their pipelines.
Keep Reading →
February 25 - News - Comments
The Motley Fool's readers have spoken, and I have heeded your cries.
Keep Reading →
February 20 - News - Comments
Today, let's look at investing giant Seth Klarman, who founded the Baupost Group hedge fund company back in 1982. Klarman is a successful investor with a lot to teach us.
Keep Reading →
February 15 - News - Comments
Stocks are rolling along unchallenged, surging to highs not seen since 2007.
Keep Reading →
February 13 - News - Comments
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Keep Reading →
February 11 - News - Comments
